Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Norton

Showing results (151-160 of 293) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Annals of Surgical Oncology|June 29, 2007
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesisTari A King, Weiwei Li, Edi Brogi, et al.
NPJ Breast Cancer|July 20, 2017
Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumorSalvatore Piscuoglio, Felipe C Geyer, Kathleen A Burke, et al.
Journal of the National Cancer Institute|September 22, 2005
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer familiesNoah D Kauff, Nandita Mitra, Mark E Robson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Genes & Development|December 25, 2015
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA lossGayatri Arun, Sarah Diermeier, Martin Akerman, et al.
Cancer Research|May 17, 2014
Slug promotes survival during metastasis through suppression of Puma-mediated apoptosisSeaho Kim, Jiahong Yao, Kimita Suyama, et al.
British Journal of Cancer|January 18, 2024
Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1αZuen Ren, Malindrie Dharmaratne, Huizhi Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
JAMA|April 13, 2006
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry, Constance Cirrincione, I Craig Henderson, et al.
Pageof 30

Showing results (151-160 of 293) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Annals of Surgical Oncology|June 29, 2007
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesisTari A King, Weiwei Li, Edi Brogi, et al.
NPJ Breast Cancer|July 20, 2017
Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumorSalvatore Piscuoglio, Felipe C Geyer, Kathleen A Burke, et al.
Journal of the National Cancer Institute|September 22, 2005
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer familiesNoah D Kauff, Nandita Mitra, Mark E Robson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Genes & Development|December 25, 2015
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA lossGayatri Arun, Sarah Diermeier, Martin Akerman, et al.
Cancer Research|May 17, 2014
Slug promotes survival during metastasis through suppression of Puma-mediated apoptosisSeaho Kim, Jiahong Yao, Kimita Suyama, et al.
British Journal of Cancer|January 18, 2024
Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1αZuen Ren, Malindrie Dharmaratne, Huizhi Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
JAMA|April 13, 2006
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry, Constance Cirrincione, I Craig Henderson, et al.
Pageof 30